Maraoui Claude 4

What Happened

• Claude Maraoui, President, CEO and a director of Journey Medical Corp (DERM), was granted equity awards on April 22, 2026: 49,277 restricted stock units (RSUs) and 82,915 stock options. The Form 4 lists the acquisition price as $0.00 for both grants (typical for awards), so the reported dollar acquisition value is $0. These were grants (transaction code A), not purchases or sales.

Key Details

• Transaction date: April 22, 2026; Form 4 filed April 24, 2026 (timely).
• Reported price: $0.00 (grants/awards are reported at $0 on Form 4).
• RSU vesting (footnote F1): 49,277 RSUs vest in thirds — 16,426 on 4/22/2027, 16,426 on 4/22/2028, 16,425 on 4/22/2029.
• Options vesting (footnote F3): 82,915 options vest in thirds — 27,638 on 4/22/2027, 27,638 on 4/22/2028, 27,639 on 4/22/2029.
• Footnote F2: confirms these include restricted stock units which vest over various time periods.
• Shares owned after the transaction are not provided in the excerpt of the filing.
• No exercise or sale occurred; these are grant/award transactions (not cashless exercises or open‑market trades).

Context

• RSUs convert to actual shares when they vest (then treated as ordinary income for tax purposes); stock options give the right to buy shares after vesting at the option’s exercise price (exercise price not shown in the provided excerpt). Grants are common for executive compensation and do not by themselves indicate immediate buying or selling intent.